Asia · General news · The Korea Herald

GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin

Published by The Korea Herald · South Korea 8 h ago

GC Biopharma and Hanmi Pharmaceutical announced on Friday that they have signed an exclusive licensing-out agreement with US biotech company BioMarin Pharmaceut ...

Read the full article on The Korea Herald Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.koreaherald.com)

Also worth reading

The Straits Times

Scottish police probe Britain’s former prince Andrew, Epstein stay at royal castle: Report

The Mainichi

India orders top drugmaker to halt eye medicine production at plant over quality lapses

Hindustan Times

GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin

Share

Also worth reading

Scottish police probe Britain’s former prince Andrew, Epstein stay at royal castle: Report

BOJ says 2% inflation target generally achieved, maintains policy rate

UK probes Meta over 'exploitative' new terms for media

(LEAD) Tigers beat Lions to stave off KBO postseason elimination

India orders top drugmaker to halt eye medicine production at plant over quality lapses

Vivek Ramaswamy seeks to become Ohio’s first Indian-American Governor: Political rise, controversies, bid against Amy Acton